Overview

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

Status:
Completed
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).
Phase:
Phase 2
Details
Lead Sponsor:
BerGenBio ASA